Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study

Kerstin Faravel, Marie-Eve Huteau, Marta Jarlier, Hélène de Forges, Laetitia Meignant, Pierre Senesse, Joanna Norton, William Jacot, Anne Stoebner

To cite this version:
Kerstin Faravel, Marie-Eve Huteau, Marta Jarlier, Hélène de Forges, Laetitia Meignant, et al.. Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study. Integrative Cancer Therapies, SAGE Publications, 2021, 20, pp.153473542110637. 10.1177/15347354211063791. hal-03706442

HAL Id: hal-03706442
https://hal.archives-ouvertes.fr/hal-03706442
Submitted on 27 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial | 4.0 International License
Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study

Kerstin Faravel, PT, MSc1, Marie-Eve Huteau, MSc1, Marta Jarlier, MSc1, Hélène de Forges, PhD1, Laetitia Meignant, MSc1, Pierre Senesse, MD, PhD1,2, Joanna Norton, PhD2, William Jacot, MD, PhD1,2 and Anne Stoebner, MD1,2

Abstract

Background: Osteo-articular pain (OAP) is experienced by approximately 50% of women under hormonal therapy (HT) for breast cancer (BC), which increases the risk for therapy discontinuation. This study was aimed to assess benefits of yoga practice combined with patient education (PE) for at-home practice by evaluating feasibility among BC patients under HT and measuring OAP, flexibility and satisfaction. Methods: Feasibility was evaluated by patient adherence as accomplishment of at least 4 out of 6 supervised yoga-PE sessions along with 70% or more at-home yoga sessions. Intervention (12 weeks) included two 6-weeks periods: P1 comprising one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga and P2, daily autonomous at-home yoga sessions. Evaluations (at inclusion and by the end of each period) consisted in assessment of OAP on Visual Analog Scale (VAS), forward flexibility (cm) and patient satisfaction on Likert (0-10 points) scale. Results: Between September 2018 and May 2019 we included 24 patients of median 53 years (range 36-72). Feasibility was validated by 83% successful adherence rate. Pain was significantly reduced from median VAS of 6 [range 4-10] to 4 [range 0-7] at the end of both P1 and P2 (p < 0.01), albeit with no difference between P1 and P2. Forward flexibility improved by a median gain of 8 cm (end of P2) and median satisfaction score of 10/10 [range 8-10]. Conclusion: Combined physiotherapy-yoga-PE intervention is a feasible strategy to increase at-home yoga practice with potential benefit on pain, flexibility, and satisfaction, thus prompting further evaluations in larger randomized multicenter trials.

ClinicalTrials.gov: NCT04001751.

Keywords

patient education, physiotherapy, breast cancer, hormonal therapy, pain, yoga

Submitted July 15, 2021; accepted November 15, 2021

Background

Breast cancer (BC) positive for estrogen receptors represents 65% to 75% of cases and requires hormonal therapy (HT) after initial treatment.1 HT is usually administered over a long period of time (5 years) and for some patients it is recommended to extend the treatment up to 10 years.2 Managing associated side-effects is a major concern regarding patients’ quality of life (QOL) and treatment adherence,3,5 given that dose reduction and treatment interruption negatively impact therapeutic effectiveness and patient survival.6,7 Non-adherence to hormonal treatment is not always easily recognized by physicians but when identified, solutions could be proposed to increase disease-free survival.8 According to a recent online survey, 31.5% of patients felt their side-effects as being underestimated by the medical team and approximately

1Cancer Institute of Montpellier, University of Montpellier, Montpellier, France
2University of Montpellier, INSERM UA11, U1194, U1298, Montpellier, France

Corresponding Author:
Kerstin Faravel, Department of Supportive care, Physiotherapy unit, Institut du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, Montpellier, 34298, France.
Email: kerstin.faravel@icm.unicancer.fr

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
one-third of patients interrupted their treatment prematurely.9 Among side-effects of HT the osteo-articular pain (OAP) also known in the literature as “joint pain”, was reported in 45% to 60% of patients under either aromatase inhibitors (AI) or tamoxifen (TM) treatment.10,11 Moreover, a recent meta-analysis showed that treatment with AI would be associated with 51% increased risk for therapy discontinuation due to side effects, including OAP.12

Patient demand for complementary therapies in symptom management has considerably increased in recent years. In North America for instance, such therapies are used by 48% to 80% of BC patients.13 The American Society of Clinical Oncology recently endorsed evidence-based guidelines for the use of complementary therapies during and after BC treatment.14 Mechanistically, the link between HT to OAP remains poorly understood, but seems to involve estrogen deprivation and/or increased levels of inflammatory markers.15 A study comparing different strategies for OAP management during HT concluded that anti-inflammatory medications, paracetamol and yoga were the most effective.16 Furthermore, numerous studies showed beneficial short-term effects of yoga for BC patients at various moments on anxiety, stress, QOL, fatigue, and pain17-22 and a few during HT. 23-26

Along this line, several previous studies suggested that the combination of supervised sessions and at-home yoga practice could increase long-term at-home yoga practice.18,19,22,23 However, to the best of our knowledge, there are no studies that integrate patient education (PE) in order to increase autonomous at-home practice. Since PE may improve yoga learning by including personal objectives to be met, it appears crucial to understand how integrated PE may improve at-home practice and what would be the level of adherence.7-29

As a first step of the SKYPE (Suivi en Kinésithérapie et Yoga - Projet Educatif) study, this investigation was aimed to assess the feasibility of intervention combining yoga with PE supervised by a physiotherapist for women with HT-induced pain following BC. Secondarily, we intended to assess potential beneficial effects of the intervention on OAP, flexibility gain and degree of patient satisfaction.

**Methods**

**Patients**

Patients were recruited among women receiving early BC treatment at the Institut du Cancer de Montpellier (ICM), France and included by the following criteria: age ≥ 18 years, non-metastatic BC, ongoing adjuvant HT and with no treatment modification over the past 30 days, OAP ≥ 4 on the pain visual analog scale (VAS), any oncologic treatment other than HT terminated at least 2 months before inclusion, written informed consent and French social security insurance cover. Exclusion criteria were: chronic rheumatologic pain with specific care management, yoga practice in 3 months prior to inclusion or contraindication to practice physical exercise. A written informed consent was obtained from all patients before inclusion. The study was approved by the French ethics committee “Comité de Protection des Personnes (CPP) Ouest VI” (May 2018) and was conducted in accordance with the Helsinki declaration and good clinical practice guidelines. The SKYPE study was registered at ClinicalTrials.gov (NCT04001751).

**Intervention: Physiotherapy, Yoga, and PE**

The intervention was carried out over 12 weeks, separated into 2 periods: P1 including supervised and at-home practice and P2 comprising only at-home yoga practice (Figure 1). Since OAP was generally experienced mostly in distal joints, the yoga postures were chosen to avoid putting body-weight on the wrists. As it is common for yoga practice, patients were encouraged to adapt postures to their limitations and capacities. A detailed description of the yoga sessions is provided in Table 1. PE was an important part of the study and theory-based on the implementation intentions model and the concept of perceived behavioral control.30-32 Thus, at the inclusion, patients were invited to define their objectives of personal yoga practice and to specify the timing, location, frequency and duration of their at-home practice (Figure 1). A minimum of 15 minutes daily yoga practice was recommended.

The first period (P1) of the study for 6 weeks aimed to initiate the learning process for at-home yoga practice benefitting from supervised sessions by a physiotherapist trained in postural yoga and PE. A minimum required training period for physiotherapists in postural yoga is 9 days, ending with a certification. One 90-minutes yoga session/week was delivered in the physiotherapy unit at the Institut du Cancer de Montpellier, for groups of maximum 5 women. Each patient received a learning kit containing a booklet on yoga practice (“My yoga guide”) and benefit from audio sessions sent by email or copied on USB stick. A logbook was also provided in order to report daily information on the regularity and duration of at-home yoga practice. The different steps of sessions were planned and detailed in accordance with “The Physiotherapist’s Guide book,” which also ensured the reproducibility of the intervention.

The second period (P2) of 6 weeks was aimed to extend the daily at-home yoga sessions learnt during previous P1 period. To reinforce motivation, the physiotherapist sent collective e-mails during weeks 2 and 4 and, on patient’s request, personal support was provided by phone.

**Outcomes**

For this feasibility study, the primary endpoint was to evaluate patient’s adherence defined as participation at 4 or more out of the 6 supervised sessions as well as the completion of 70% or more home-sessions. For the P1 supervised sessions, the physiotherapist recorded participation. Adherence to home sessions during the 12 weeks of P1 and P2 was evaluated from data registered in the patient’s-completed logbooks. The initial
evaluation (E0) was performed at inclusion; the intermediate evaluation (E1) was defined at the end of P1 and the final evaluation (E2) at the end of P2. At inclusion (E0), socio-demographic and clinical characteristics of patients were also collected: age, weight, body mass index (BMI), TNM stage of BC, previous and current oncologic treatments as well as the geographic distance between their home and the hospital.

For secondary endpoints, the physiotherapist used VAS (from 0 to 10) to measure the maximum intensity of HT-associated OAP during the previous week. Flexibility was evaluated by measurement of the distance between fingertip and the floor while the patient was bending forward, keeping knees straight and feet together and placed on a step. Values were expressed as median and range (in cm). Negative values (under the floor level) indicated more flexibility. Satisfaction of patients for the intervention was evaluated at E1 and E2 using Likert scale ranging from 0 to 10 points. Adverse effects were recorded at all assessments or supervised sessions according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. Other possible limitations for yoga practice were noted by the physiotherapist such as lymphedema, scar tightness and movement limitations.

**Statistical Considerations**

Sample size was calculated using a single-stage Fleming design. With \( \alpha \) set at 0.05, the 82% power and \( p_0 \) and \( p_1 \) values of 50% and 75%, respectively, a sample size of 24 patients was required for this study. The feasibility was considered when at least 16 of the 24 patients adhered to the intervention. The adherence rate was expressed with 95% confidence interval (95% CI). Categorical variables were described using frequencies and percentages and continuous variables using median and range. A non-parametric Wilcoxon paired test was used to compare OAP between evaluations at E0, E1, and E2. The statistical significance level was set at \( p < .05 \). Data were analyzed using Stata version 16 (StataCorp LP, College Station, TX).

**Results**

**Patients**

Of the 41 eligible women who were approached between September 2018 and May 2019, a proportion of 58.5% agreed to participate (Figure 1). The main reasons for refusing were: not available/too busy (19.5%), lived too far away

---

**Figure 1.** Flow diagram of participant recruitment and main steps in the intervention.
(17%), bothered by others looking at me (2.5%) and not interested (2.5%). After acceptance, 24 women were included in the study displaying a median age of 53 years [range 36-72]. Regarding previous treatments, all women undergone breast surgery combined with sequential anthracyclines-taxanes chemotherapy (71%) and/or radiotherapy (92%) (Table 2).

**Feasibility and Adhesion**

Of the 24 women, 20 patients have met the criteria for adherence to the intervention, including those who completed 70% (55 out of the expected 78) at-home sessions, which represents 83% adherence rate, 95% CI [62.6%-95.3%]. Among the remaining 4 patients, 2 dropped-out, 1 before and 1 after the first supervised session, and another 2, although they completed supervised sessions, did not fulfill required number for at-home sessions. Eighteen patients among all 24 women (75%) attended 6 supervised sessions, 3 attended 5 sessions, and 1 attended 4 sessions. The number of performed at-home sessions was in median 74 [range: 43-83] with a median duration of 15 minutes [range 8-105]. Seven of 24 women (29%) completed all and sometimes even more than required number of at-home sessions, 13 patients (54%) completed 70-99% of at-home sessions and 2 patients (8.3%) did not complete the required numbers of at-home sessions and another 2 (8.3%) did not participate in the supervised sessions.

**Osteo-articular Pain, Flexibility, Patient’s Satisfaction, and Adverse Effects**

A significant reduction in OAP was reported between E0 and E1 with median value of 6 [range 4-10] for E0 and 4 [range: 0-7] for E1 (p <.01) as well as between E0 and E2: median 6 [range: 4-10] and 4 [range: 0-7] (p <.01), respectively (Figure 2). However, there was no significant difference in pain reduction between E1 and E2 (p = .09). For 14 patients (58.3%) the reduction between E0 and E2 in pain intensity was at least 2 points on VAS.

Significant increase in forward flexibility was reported between the start and the end of each period. Between E0 and E1 (P1 period) the median value dropped from 4 cm (range 18 to −7) to −2.5 cm (range 13 to −11), respectively. Between E1 and E2 the median value dropped further from −2.5 to −4 cm (range 10 to −14). Thus, the overall median gain between E0 and E2 at the end of the study was 8 cm (Figure 2).

---

**Table 1. Detailed Description of Yoga Sessions.**

| Period     | Supervised by physiotherapist | Home practice |
|------------|-------------------------------|--------------|
| Number     | Only during P1                 | During P1 and P2 |
| sessions   | 6                              | 78           |
| Duration   | 1 h 30 min                     | ≥15 min      |
| Total      | 9 h                            | 9 h (P1) and 10 h 30 (P2) |
| Content    | Welcome, handing-in of the previous week logbooks (5') | 10 numbered postures |
|            | Introduction (5')              | 6 lying down and 4 standing up, with movements of flexion, extension, stretching, rotation and balance. |
|            | Sharing/exchanging of experiences (10') | No pressure on wrists. |
|            | Philosophical perspective (10') | 1. Savasana and body scan |
|            | Postural yoga (Asanas) + relaxation (30') | 2. Savasana and hand rotation etc. |
|            | - Session 1-2 learning of “My Yoga guide” | 3. Half side stretch |
|            | - Session 3-6 introduction to other postures | 4. Jathara parivrti knees bent |
|            | • Ardha uttanasana              | 5. Dvipada pitham |
|            | • Parsva uttanasana             | 6. Apanasana |
|            | • Utkatasana                    | 7. Uthita trikonasana 2 |
|            | • Urdhva prasrta padasana       | 8. Uttanasana |
|            | • Pascimatanasana               | 9. Uthita trikonasana 1 |
|            | • Virabhadrasana                | 10. Tadasana |
|            | • Prasrita pada uttanasana      | **Option 1:** |
|            | • Upavista konasana             | Recommended as aid for waking-up: |
|            | Breathing exercises: Pranayama (10') | sequence of postures from 1 to 10 (lying down first, then standing postures). |
|            | • Ujjayi                        | **Option 2:** |
|            | • Nadi sodhana                  | Recommended for evening relaxation: |
|            | Sharing personal experience about session (10') | sequence of postures from 10 to 1 (standing first, then lying down postures) |
|            | Definition of personal educational objectives (5') | |
|            | Conclusion (5')                | |
The median satisfaction score about patient’s participation evaluated at E1 and E2 was 10/10 [range 8-10]. No adverse events related directly to the yoga practice were reported during the study. There were no significant differences (p > .4) for all parameters already indicated (pain, flexibility, and satisfaction) between the group of patients under treatment with AI (n = 15) or TM (n = 9).

Discussion

Our study reported 83% adherence rate to physiotherapy-yoga-PE for BC patients under HT and displaying OAP whatever the HT used. In addition, we reported a significant reduction in HT-induced OAP by the end of study and amelioration of flexibility and degree of satisfaction. These data taken together highlight the feasibility of the intervention and beneficial effects while the absence of adverse events and high level of satisfaction indicate that the intervention met patients’ expectations and needs. This study represents a crucial step in further randomized interventional programs such as the SKYPE2 protocol initiated by our institution (NCT04457895). In face of quite low adherence of yoga practice at-home, our results reinforce the concept that PE combined with supervised sessions might increase the autonomy for at-home yoga practice. Thus, using the concept of implementation intentions and distance learning, the adherence of such programs is expected to increase among BC patients, particularly in the context of Covid-19 outbreak sanitary crisis.

The good adherence rate highlights the feasibility of an intervention combining physiotherapy, yoga, and PE. Moreover, the absence of severe adverse events suggests a safety strategy concordant to previous reports. The 58.5% high participation rate among patients initially approached for the study confirmed the growing interest and demand for non-pharmacological interventions in BC patients. It should be indicated that participation rates for similar studies in the literature ranged from 23.3% to 56%. The main reasons for refusal are in general the geographical distance or transportation difficulties. Offering supervised video sessions could increase participation and the ongoing Covid-19 sanitary crisis has accelerated the development of such distance learning in order to ensure continuity of care.

Among patients included in the study, the high adherence to our protocol (83%) and the high satisfaction level (10/10 at both E1 and E2) suggested that intervention met patients’ expectations and needs. Indeed, some BC patients expressed the feeling of being abandoned by the health care system in the management of their symptoms during adjuvant HT period. Similar feedback of patients has been reported for instance, by French National Cancer Institute in the VICAN survey (Life 5 years after a cancer diagnosis). This explains why support, listening and follow-up offered by our protocol appeared particularly relevant at this point of the care pathway.

We aimed to increase the adherence to our program by integrating PE into the protocol in order to optimize the learning process and autonomy in practicing at-home yoga. In this goal, we used the concept of implementation intentions and helped each patient to identify early their personal resources and perceived potential obstacles. Patients were also encouraged to anticipate the time-window, place and equipment necessary for at-home sessions taking into account various constraints and symptom management. We believe that this self-management may have reinforced patient’s feeling of self-efficacy and security.

Previous similar studies in this field used slightly different designs and content. Thus, some studies offered 2 weekly sessions of similar length than ours, but did not include at-home practice. Others included at-home practice, but without PE programs. Two studies offered a 4:1 ratio of supervised over home-practice cumulated duration. However, these above cited studies evaluated

| Table 2. Patients’ Characteristics at Baseline. |
|-----------------------------------------------|
|                                | Patients (n = 24) |
| Age (years), median [range]          | 53 [36-72]       |
| BMI (kg/m²), n (%)<sup>a</sup>        |                  |
| Underweight (<18.5)                  | 1 (4)            |
| Normal (18.5-25)                     | 12 (50)          |
| Overweight (25-30)                   | 9 (38)           |
| Obese (≥30)                          | 2 (8)            |
| Physical activity, n (%)             |                  |
| None                                 | 2 (8)            |
| Occasional<sup>b</sup>               | 10 (42)          |
| Frequent<sup>c</sup>                 | 12 (50)          |
| TNM stage<sup>d</sup> (T), n (%)      |                  |
| T1                                   | 16 (67)          |
| T2                                   | 8 (33)           |
| TNM stage<sup>d</sup> (N), n (%)      |                  |
| N0                                   | 14 (59)          |
| N1                                   | 8 (33)           |
| N2                                   | 2 (8)            |
| Previous treatments, n (%)           |                  |
| Surgery                              | 24 (100)         |
| Radiotherapy                         | 22 (92)          |
| Chemotherapy                         | 17 (71)          |
| Current hormone therapy, n (%)       |                  |
| Tamoxifen (TM)                       | 9 (37)           |
| Letrozole (AI)                       | 10 (42)          |
| Exemestane (AI)                      | 4 (17)           |
| Anastrozole (AI)                     | 1 (4)            |

<sup>a</sup>Body Mass Index.
<sup>b</sup>Activity equivalent to a 30-minute walk : 1 to 3 times a week.
<sup>c</sup>Activity equivalent to a 30-minute walk 4 times/week and more.
<sup>d</sup>TNM, Classification of Malignant Tumors.
mainly supervised sessions with limited information on how at-home sessions were organized and assessed. Thus, our study appears original in combining supervised and at-home practice sessions. We promoted a reduced cumulated duration of supervised sessions in favor of an increased duration for at-home practice. Thus, the recommended ratio was 1:1 for the P1 period and 1:2 for the entire study. PE was integrated to encourage autonomy and thus to allow a reduced number of supervised sessions. This could be of particular interest for patients living far from the hospital and for whom there are limited resources and healthcare facilities.

In addition, our study showed a significant reduction in OAP between E0 and E1 and between E0 and E2. The rapid reduction in OAP intensity, which lasted over the whole intervention, highlights the short-term efficacy of our protocol. The benefit was observed very early, thus keeping patients’ motivation and adherence. These findings are in accordance with other studies showing the beneficial effect of yoga on HT-induced pain in BC patients.\textsuperscript{23,24} Moreover, a reduction in OAP for at least 2 VAS points at final evaluation was reported for 58\% of patients. The remaining 42\% had no change in pain intensity or a weaker (only 1 point) reduction. Women were asked to differentiate between pain linked to HT and other types of pain. However, some women reported that, regardless of pain intensity, the nature of pain and their personal approach to accept the pain have somewhat changed. This was illustrated for example by the following statements: «I feel better in my body», «I accept the pain, I live with it», «I have learnt to force myself less, and to listen more to my body». It should be indicated that adherence to the intervention also depends on multiple other factors such as working outside of the home, marital status, having children in the home and availability of support with childcare. These data suggest the intervention of several psychological components. Therefore, the use of more elaborated multi-dimensional pain scales, such as Brief Pain Inventory would be in our view essential for future studies.\textsuperscript{38,39} Indeed, management of HT-induced pain is multifactorial and the qualitative exploration of Galantino et al already indicated the importance of emerging themes, such as empowerment, community, sharing, and relieved stress.\textsuperscript{40}

Although the study was not designed to compare effects of yoga practice among patients under AI or TM, as indicated in the results section, there were not statistical differences with nonparametric tests between 2 groups for any of parameters studied. However, it should be indicated that the drop in the absolute values of pain and flexibility was somewhat more significant in the AI group than TM group. Thus, the drop between E0 and E1 or between E0 and E2 were more significant for the AI group ($p<.0036$ and $.0099$) than for the TM group ($p<.03$ and $.05$), respectively. Similar observation was done in the amelioration of the flexibility between E0 and E1 and between E0 and E2: $p<.0011$ and .0015 for group AI, respectively and $p<.13$ (NS) and .011, respectively for TM group. While no such differences were found for the satisfaction, our data cannot exclude the possibility of additional different effects as function of the hormonal treatment. These data should be interpreted however with caution since the number of

![Figure 2. Osteo articular pain and flexibility values by visit.](Image)
patients in each group were low and different among treatment groups. Further studies on larger sizes would be necessary to conclude on these aspects.

The adverse effects in this study also deserve discussion. Indeed, no adverse effects were reported related to the yoga practice. It should be however indicated that adverse effects were noted related with the HT, which did not enter into the scope of this feasibility study. While no differences were found between AI and TM groups for OAP, hot flashes, weight gain, nausea, insomnia, headache and migraine, some significance was observed for fatigue (86.7% grade 1 in AI group and only 33.3% in TM group, \(p < .021\)). Although differences might exist between 2 groups, very likely these were due to the hormonal treatment since they were present already at the inclusion and did not appear during the yoga practice. They were classified as gastrointestinal effects (nausea—grade 2 or diarrhea—grade 1) and musculo-skeletal abnormalities (pain—grade 1) found for AI group and rather musculo-skeletal abnormalities (pain—grade 2) and vascular manifestations (hot flashes—grade 1) for the TM group.

**Limitations**

The main limitation of our study was the lack of a randomized control group to test the efficacy of intervention. Indeed, this one arm study was performed with the objective to evaluate feasibility, which, given the commitment required from patients, was a crucial step in such interventional studies. Even under these conditions, our observation on pain reduction and amelioration of flexibility as well as the degree of satisfaction were concordant with the adherence rate. Further comparative group studies would be necessary to confirm these observations in quantitative terms. Another limitation would be the relative small sample size, which was however statistically powered in this study and which remains comparable to other studies evaluating feasibility of yoga interventions.22,34 Finally, the heterogeneity of patient population regarding the used HT (TM as selective modulator of estrogen receptors vs AI) could also be considered as a limitation. This is explained by the main criterion for inclusion as the presence of HT-induced OAP regardless the molecule used in the HT. Thus, although no significant differences were detected between these 2 groups concerning adherence, pain, flexibility of satisfaction, potential differences could exists, which deserve further more specific investigation.

**Conclusion**

This study highlighted the feasibility of offering an intervention to BC women experiencing pain from HT combining supervised yoga sessions by a physiotherapist with PE based on the concept of implementation intentions for at-home yoga practice. Our findings suggest that our intervention is highly feasible, safe and well appreciated by the patients. The effectiveness of this intervention on pain and other factors affecting patients’ QOL are currently evaluated in an on-going randomized controlled trial.

**Acknowledgments**

We are very grateful to patients who participated in the study and all ICM teams, including Dr Maryvonne Soulier. We extend our thanks to research assistants Manon Sire and Caroline Constant and physiotherapy students Cécile Egron-Reverseau and Olivia Blanc for recruitment and data collection. We are also thankful toward Mathieu Gourlan for providing information on the concept of implementation intentions and Florin Grigorescu (florin.grigorescu@icm.unicancer.fr) for revising the manuscript.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Canceropole GSO grant (#2017-E16), which did not contribute to design, data collection and interpretation and decision to publish.

**ORCID iD**

Kerstin Faravel [https://orcid.org/0000-0003-1231-1108](https://orcid.org/0000-0003-1231-1108)

**References**

1. Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. *N Engl J Med*. 2020;383:2557-2570.
2. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. *J Clin Oncol*. 2019;37:423-438.
3. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. *J Clin Oncol*. 2008;26:556-562.
4. Oberguggenberger A, Hubalek M, Sztankay M, et al. Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). *Breast Cancer Res Treat*. 2011;128:553-561.
5. Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. *J Clin Oncol*. 2008;26:556-562.
6. Oberguggenberger A, Hubalek M, Sztankay M, et al. Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). *Breast Cancer Res Treat*. 2011;128:553-561.
7. Niravath P. Aromatase inhibitor-induced arthralgia: a review. *Ann Oncol*. 2013;24:1443-1449.

7. Niravath P. Aromatase inhibitor-induced arthralgia: a review. *Ann Oncol*. 2013;24:1443-1449.
8. Pistilli B, Paci A, Ferreira AR, et al. Serum detection of non-adherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol. 2020;38:2762-2772.
9. Berkowitz MJ, Thompson CK, Zibecchi LT, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surviv. 2021;15:29-39.
10. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25:3877-3883.
11. Linternmans A, Van Asten K, Wildiers H, et al. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat. 2014;146:109-116.
12. Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Res Treat. 2020;179:275-285.
13. Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and following breast cancer treatment. CA Cancer J Clin. 2017;67:194-232.
14. Lyman GH, Greenlee H, Bohlke K, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol. 2018;36:2647-2655.
15. Gupta A, Henry NL, Loprinzi CL. Management of aromatase inhibitor-induced musculoskeletal symptoms. J Oncol Pract. 2020;16:733-739.
16. Lombard JM, Zdenkowski N, Wells K, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. Support Care Cancer. 2016;24:2139-2146.
17. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 2017;1:CD010802.
18. Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga’s impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32:1040-1049.
19. Chandwani KD, Perkins G, Nagendra HR, et al. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol. 2014;32:1058-1065.
20. Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer. 2012;118:3766-3775.
21. Rao RM, Vadiraja HS, Nagaratha R, et al. Effect of yoga on sleep quality and neuroendocrine immune response in metastatic breast cancer patients. Indian J Palliat Care. 2017;23:253-260.
22. Komatsu H, Yagasaki K, Yamauchi H, Yamauchi T, Takebayashi T. A self-directed home yoga programme for women with breast cancer during chemotherapy: a feasibility study: yoga for patients undergoing chemotherapy. Int J Nurs Pract. 2016;22:258-266.
23. Galantino ML, Desai K, Greene L, Demichelle A, Stricker CT, Mao JJ. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther. 2012;11:313-320.
24. Peppone LJ, Janelins MC, Kamen C, et al. The effect of YOCAS® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast Cancer Res Treat. 2015;150:597-604.
25. Jacobsen PB, Muchnick S, Marcus S, et al. Pilot study of iyengar yoga for management of aromatase inhibitor-associated arthralgia in women with breast cancer. Psychooncology. 2015;24:1578-1580.
26. Cramer H, Rabsilber S, Lauche R, Kümmel S, Dobos G. Yoga and meditation for menopausal symptoms in breast cancer survivors: a randomized controlled trial. Cancer. 2015;121:2175-2184.
27. Bonnabel L, Huteau M-É, Filhol N, et al. [Combining clinical pathway and patient education approaches]. Rev Infirm. 2016;65:38-40.
28. Haute Autorité de Santé. Structuration d’un programme d’éducation thérapeutique du patient dans le champ des maladies chroniques; 2007. Accessed April 24, 2019. https://www.has-sante.fr/portail/jcms/c_601290/fr/structuration-d-un-programme-d-education-therapeutique-du-patient-dans-le-champ-des-maladies-chroniques.
29. Howell D, Harth T, Brown J, Bennett C, Boyko S. Self-management education interventions for patients with cancer: a systematic review. Support Care Cancer. 2017;25:1323-1355.
30. Gollwitzer PM. Weakness of the will: is a quick fix possible? Motiv Emot. 2014;38:305-322.
31. Hagger MS, Luszczynska A. Implementation intention and action planning interventions in health contexts: state of the research and proposals for the way forward. Appl Psychol Health Well Being. 2014;6:1-47.
32. Azjen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179-211.
33. Machin D, Campbell M, Tan S, et al. Sample Size Tables for Clinical Studies. 3rd ed. Wiley-Blackwell; 2011.
34. Baydoun M, Barton DL, Peterson M, et al. Yoga for cancer-related fatigue in survivors of hematopoietic cell transplantation: a feasibility study. J Pain Symptom Manag. 2020;59:702-708.
35. Danhauer SC, Addington EL, Cohen L, et al. Yoga for symptom management in oncology: a review of the evidence base and future directions for research. Cancer. 2019;125:1979-1989.
36. Institut National du Cancer. La vie cinq ans après un diagnostic de cancer. Institut National du Cancer; 2018:364.
37. Wieber F, Thürmer JL, Gollwitzer PM. Promoting the translation of intentions into action by implementation intentions: behavioral effects and physiological correlates. Front Hum Neurosci. 2015;9:9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500900/.
38. Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain. 2003;4:2-21.
39. Andersson V, Bergman S, Henoch I, Simonsson H, Ahlberg K. Benefits of using the brief pain inventory in patients with cancer pain: an intervention study conducted in Swedish hospitals. Support Care Cancer. 2020;28:3721-3729.